Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Beleave in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in Beleave. This rating has held steady since February 2020, when it changed from a Buy consensus rating.
Beleave Inc., together with its subsidiaries, cultivates, produces, and sells tetrahydrocannabinol and cannabidiol medical cannabis in Canada and Colombia. The company produces cannabis oils and extracts for medical purposes. It also operates a network of medical cannabis clinics under the Medi-Green banner. Beleave Inc. is headquartered in Hamilton, Canada.